Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Jul 24, 2018

SELL
$19.2 - $25.14 $1,536 - $2,011
-80 Closed
0 $0
Q4 2017

Feb 02, 2018

SELL
$11.37 - $16.4 $1,512 - $2,181
-133 Reduced 62.44%
80 $1,000
Q3 2017

Oct 20, 2017

BUY
$9.93 - $15.47 $2,115 - $3,295
213
213 $3,000

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.